Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Authors not listed
Novartis Pharmaceuticals · 2020
Abstract
This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2020). Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health). <em>Novartis Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT05146687
Vancouver
Anonymous. Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health). Novartis Pharmaceuticals. 2020.
BibTeX
@misc{anon2020Realwo,
title = {Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)},
author = {Anonymous},
journal = {Novartis Pharmaceuticals},
year = {2020},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Science 2006
Citation only
HTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
Advanced Drug Delivery Reviews 2005
Citation only
Wet age-related macular degeneration
Bayer 2019
Open access · US-GOV
Evaluation of an eXtended and proacTive Dosing regimEn in Treatment-Naïve Patients With Wet Age-related Macular Degeneration (wAMD)
Akademisyen Kitabevi eBooks 2025
Open access · OA
Uzun Yaşam Diyeti
Alcon Research 2005
Open access · US-GOV
Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)
Snyder, Robert W., M.D., Ph.D., P.C. 2017
Open access · US-GOV